Illumina offers EU concessions over Grail deal as merger-review clock restarts
US biotech company Illumina has today offered to change the terms of its deal to acquire cancer-testing specialist Grail in a bid to assuage EU competition concerns over the transaction, according...To view the full article, register now.
Already a subscriber? Click here to view full article